-
Study aim
-
Evaluation of the therapeutic effect of the active form of vitamin D in the treatment of patients with acute renal failure Renal type
-
Design
-
Patients were randomly divided into two groups of 38 using random allocation software. The numbered envelopes will be arranged from 1 to 76, respectively, and within each envelope the type of treatment is specified, which will be implemented after the treatment envelope is opened.
-
Settings and conduct
-
This double-blind parallel clinical trial study will be performed on acute renal failure patients referred to the emergency department of Imam Hossein Shahroud Hospital.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Ages over 18 years, Acute kidney failure according to KDIGO criteria, Having informed consent to participate in the study, Hospitalized in the usual ward, ICU CCU of Imam Hossein Shahroud Hospital, Non-return of creatinine to normal within 48 hours despite fluid replacement or granular and epithelial casts, Ability to eat or own NG Tube, No history of kidney disease and kidney transplant, No history of taking vitamin D compounds for the past 7 days, No active primary parathyroid disease or active granulomatous disease or symptomatic nephrolithiasis in the past 3 months, No pregnancy, no breastfeeding. Exclusion criteria: Administration of cytochrome p450 inhibitors, hemoglobin lower than 7
-
Intervention groups
-
The study will be randomly divided into two groups of 38. The case group received 0.25 mg rocanrolol tablets, except for routine renal injury treatment. In the control group, patients will receive no medication other than routine treatment of acute kidney injury.
-
Main outcome variables
-
Kidney function The blood urea and creatinine levels are measured